Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
The national child abuse inquiry is to hold its first hearing on Monday, beginning with the child migration programme.
Monday will be a breezy day for many, especially in the south.
Three-quarters of Britons polled said they would support more sex and relationship education in schools.